维普中文期刊产品整合服务
43篇 您的检索式:作者名="MEREDITH A L"
    题名 作者 年代 出处 被引量
1Identification of associations between SSR markers and fiber traits in an exotic germplasm derived from multiple crosses among Gossypium tetraploid species显示文摘Zeng L H Meredith W R Jr Gutiérrez O A 2009Theor Appl Genet2009,119,:1
2Grain refinement of aluminium alloys by inoculation 显示文摘GREER A L COOPER P S MEREDITH M W SCHNEIDER W SCHUMACHER P SPITTLE J A 2003Advanced Engineering Materials2003,5,:1
3Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol显示文摘Elliot H L Meredith P A Sumner D J 1984Br J Clin Pharmac1984,17,5:1
4Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade : further analysis of the ACTION database inpatients with angina显示文摘Elliott H L Meredith P A 2011J Hum Hypertens2011,25,8:1
5Lean implementation in primary care health visiting services in National Health Service UK 显示文摘Grove A L Meredith J O Macintyre M 2010Quality and Safety in Health Care2010,19,5:1
6polychlorinated biphenyl accumula- tion in tree bark and wood growth rings显示文摘Meredith M L Hites R A 1987Environmental Sci- ence & Technology1987,21,:1
7Thrapeutic equivalence in the treatment of hypertension:Can lercanidipine and nifedipine GITS be considered to be interchangeable?显示文摘AIM: To undertake a review of the evidence that nifedipine GITS and lercanidipine are therapeutically equivalent in the management of essential hypertension.METHODS: A systematic review of the published literature was prompted by the findings of two meta-analyses which indicated that there was a lower incidence of peripheral(ankle) oedema with lercanidipine. However,neither meta-analysis gave detailed attention to comparative antihypertensive efficacy or cardiovascular protection. Accordingly,a systematic,detailed and critical review was undertaken of individual published papers. The review started with those studies incorporated into the 2 meta-analyses and then all other salient and directly relevant papers identified through the following search criteria: all randomized controlled trials in which the therapeutic profile and antihypertensive effects of lercanidipine were directly compared with those of nifedipine GITS(in hypertensive patients). The searchstrategy was focused on the reports of clinical trials of lercanidipine vs nifedipine GITS,which were identified through a systematic search of PubMed(from 1966 to October 2012),Embase(from 1980 to October 2012) and the Cochrane library(from 1 October 2008 to end October 2013). The search combined terms related to lercanidipine vs nifedipine GITS(including MeSH search using calcium antagonists,calcium channel blockers and dihydropyridines).RESULTS: With regard to blood pressure(BP) control and the consistency of BP control throughout 24-h,there is limited published evidence. However,two studies using 24 h ambulatory blood pressure monitoring clearly identified the dose-dependency of BP lowering with lercanidipine and its variably sustained 24-h efficacy. In contrast,there is evidence of a consistent antihypertensive effect throughout 24 h with nifedipine GITS. The incidence of the most common 'side effect',i.e.,peripheral(ankle) oedema can be estimated as follows. For every 100 patients treated with lercanidipine,2.5 will report oedema compared to 6 patients treated with nifedipine GITS. However,98 or 99 patients will continue treatment with nifedipine GITS,compared with 99.5 patients on lercanidipine. Finally,with regard to outcome studies of cardiovascular(CV) morbidity and mortality,there is definitive outcome evidence for nifedipine GITS but there is no evidence that treatment with lercanidipine leads to reductions in CV morbidity and mortality.CONCLUSION: There is no evidence in terms of longterm BP control and CV protection to justify the contention that lercanidipine is therapeutically equivalent to nifedipine GITS.Henry L Elliott Peter A Meredith 2014World Journal of Cardiology2014,6,6:1
8Prevalence of comorbid anxiety discovers in primary care outpa- tients显示文摘SHERBOURNE C D JACKSON C A MEREDITH L S 1998Arch Fam Med1998,17,1:1
9Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder显示文摘THORNELOE K S MEREDITH A L KNORN A M 2005Am J Physiol Renal Physiol2005,289,3:1
10Chronic bacterial endophthalmitis显示文摘Ficker Meredith T A Wilson L A 1987Am J Ophthalm ol1987,103,:1
11Diagnostic ac- curacy of transvaginal sonography for the diagnosis of adeno- myosis: systematic review and metaanalysis显示文摘Meredith S M Sanchez Ramos L Kaunitz A M 2009Am J ObstetGynecol2009,201,1:1
12Polychlorinated biphenyl accumulation in tree bark and wood growth tings显示文摘Meredith M L Hites R A 1987 1987Environ Sci Technol1987,21,:1
13FAK regulates cardiomyocyte surviv-al following ischemia/reperfusion显示文摘Hakim Z S?DiMichele L A Rojas M Meredith D MackC P Taylor J M 2009J Mol Cell Cardi-ol2009,46,:1
14Alteration in cardiac gene expression during the transitionl from stable hypertrophy to heart failure显示文摘Boluyt M O Oneill L Meredith A L 1994Circ Res1994,75,:1
15Overactive bladder and incontinence in the absence of the BK large conductance Ca^2 + -ac- tivated K^+ channel 显示文摘Meredith A L Thomeloe K S Wemer M E 2004J Biol Chem2004,279,36:1
16Effect of suspending exercise training on resting metabolic rate in women显示文摘HERRING J L MOLE P A MEREDITH C N 1992Med Sci Sports Exe1992,24,1:1
17Occlusion cuff po sition is an important determinant of the time course and mag- nitude of human brachial artery flow mediated dilation显示文摘Berry K L Skyrme Jones R A Meredith I T 2000Clin Sci2000,,:1
18Grain Refinement of aluminum alloys by inoculation 显示文摘GREER A L COOPER P S MEREDITH M W 2003Advanced Engineering Materials2003,5,12:1
19Minimallyinvasive surgery for esophageal cancer显示文摘Santillan A A Farma J M Meredith K L 2008J Natl Compr CancNetw2008,6,9:1
20Doxazosin, an alpha 1-adrenoceptor antagonist:pharmacokinetics and concentration-effect relationships inman 显示文摘VINCENT J ELLIOTT H L MEREDITH P A 1983Br J Clin Pharm1983,15,6:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费